Why This $900 Stock May Announce a Split in 2026
Eli Lilly shares traded near $967.14 recently, rising about 5.15% or $47.37 on the session. The stock sits among high-priced names that often attract split talk. Investors are watching fundamentals and corporate signals closely.
Strong commercial momentum
The company has become a leader in obesity and metabolic treatments. Its GLP-1 medicines Mounjaro and Zepbound drove steep sales gains in 2025.
- Mounjaro revenue grew about 99% year over year to nearly $23 billion.
- Zepbound revenue jumped roughly 175% year over year to about $13.5 billion.
Despite the surge, GLP-1 penetration is still in the mid-single digits among eligible U.S. patients. That suggests a large addressable market remains.
Financial results and guidance
In fiscal 2025, total revenue rose about 45% year over year to roughly $65.2 billion. Earnings per share increased about 86% to $24.20.
Management guided fiscal 2026 revenue to a range of $80 billion to $83 billion. They expect pricing to weigh on growth by the low- to mid-teens percentage. Volume gains should more than offset that drag.
Pipeline and capacity build-out
The company plans to expand its manufacturing footprint. Since 2020, it has committed more than $55 billion to capacity and production projects.
It also lists 36 active late-stage, phase 3 programs. An oral GLP-1 candidate, orforglipron, could reach patients who avoid injections.
Market profile and valuation metrics
| Current price | $967.14 |
| Market cap | $869 billion |
| Day’s range | $925.65 – $970.00 |
| 52-week range | $623.78 – $1,133.95 |
| Volume (today) | 139,000 |
| Avg. volume | 3.2 million |
| Gross margin | 83.04% |
| Dividend yield | 0.68% |
Why a split is being discussed
Stock splits do not change a company’s cash flows or fundamentals. They can improve liquidity and broaden the investor base.
High absolute share prices, like those of this $900 stock, often prompt shareholders to ask whether management will announce a split. Given recent price gains and strong revenue momentum, a move to split shares could be possible in 2026.
What to watch next
Track quarterly volume trends for Mounjaro and Zepbound. Watch uptake of orforglipron after any regulatory milestones.
Also monitor capital spending updates and comments from management about capital allocation. Any explicit comment about share structure would be a clear signal.
Filmogaz.com will continue to follow developments and report material changes in results or corporate actions.
